Cardiology News /Recent Literature Review / First Quarter 2012
Keywords:
cardiology, electrophysiology, cardiac pacing, newsAbstract
The Athens Cardiology Update 2012 is slated for April 5-7, 2012
The HRS 33rd Meeting will be held in Boston, 9-12/5/12
The ESC Congress will be held in Munich, 25-29/8/2012
TCT Meeting will take place in Miami, 22-26/10/12
HCS Meeting to be held in Athens, 1-3/11/12
AHA 2012 is scheduled for Los Angeles, 3-7/11/12
PARTNER Trial (Cohort B): TAVI Remains Cost-Effective for Patients with Severe Aortic Stenosis who are not Candidates for Surgery
The PARTNER trial randomized patients with symptomatic, severe aortic stenosis who were not candidates for surgery to transcatheter aortic valve implantation (TAVI) (n=179) or standard therapy (n=179). Mean costs for the initial TAVI procedure and hospitalization were $42,806 and $78,542, respectively. Follow-up costs through 12 months were lower with TAVI ($29,289 vs $53,621) because of reduced hospitalization rates, but cumulative 1-year costs remained higher ($106,076 vs $53,621). Projection was that over a patient’s lifetime, TAVI would increase discounted life expectancy by 1.6 years (1.3 quality-adjusted life-years-QALY) at an incremental cost of $79,837. The incremental cost-effectiveness ratio for TAVI was thus estimated at $50,200 per year of life gained or $61,889 per QALY gained. The authors concluded that TAVI increases life expectancy at an incremental cost per life-year gained well within accepted values for commonly used cardiovascular technologies. (Reynolds MR et al, Circulation 2012;125:1102-1109).
SCAAR Registry: Lower Risk of Stent Thrombosis & Restenosis with Unrestricted Use of ‘New-Generation’ Drug-Eluting Stents
A total of 94,384 consecutive stent implantations, including bare metal (BMS, n=64,631), older generation drug-eluting stents (o-DES, n=19,202), and new generation DES (n-DES, n = 10 551) were evaluated in Sweden. Older generation DES comprised Cypher and Cypher Select, Taxus Express and Taxus Liberte, and Endeavor Sprint, while n-DES included Endeavor Resolute, XienceV, Xience Prime, Promus, and Promus Element. A statistically significant lower risk of restenosis was shown for n-DES compared with BMS [adjusted hazard ratio (HR) 0.29] and o-DES (HR 0.62). A lower risk of definite ST was found in n-DES compared with BMS (HR 0.38) and o-DES (HR, 0.57). The risk of death was significantly lower in n-DES compared with o-DES (adjusted HR: 0.77) and BMS (adjusted HR: 0.55). The authors concluded that PCI with n-DES is associated with a 38% lower risk of clinical restenosis, a 43% lower risk of definite ST, and a 23% lower risk of death compared with o-DES (Sarno G et al, Eur Heart J 2012;33:606-613)... (excerpt)
Downloads
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
